Pacific Biosciences reported a 14% year‑over‑year revenue increase in Q4, driven by stronger demand in Europe and rising clinical adoption of its long‑read platforms. The company shipped multiple Revio and Vega instruments and recorded record consumables revenue, signaling solid pull‑through from installed systems. PacBio highlighted expanding clinical whole‑genome sequencing use for rare disease and growing Vega benchtop placements. Management flagged ongoing headwinds in academic capital spending but said product‑led clinical adoption and new reagent launches should support modest growth and margin expansion in 2026.